Abstract
Multipurpose prevention technologies (MPTs) designed to simultaneously prevent pregnancy and HIV could provide urgently needed tools to address unmet sexual and reproductive health needs of women worldwide. Late-stage clinical trials will be complex given the need to demonstrate efficacy for HIV and contraceptive indications simultaneously from a single product. Currently, HIV and pregnancy prevention trials have distinctive design features that will need to be reconciled in MPT trials. This article identifies several ethical issues uniquely associated with this research that will benefit from future deliberation and guidance to ensure that this globally important research can proceed efficiently and expeditiously.
Funding Information
  • United States Agency for International Development (#AID-OAA-A-11-00051)
  • National Institutes of Health (1 R56 AI108368-01)
  • United States Agency for International Development (USAID) (AID-OAA-A-11-00051)
  • National Institutes of Health (1 R56 AI108368-01)
  • United States Agency for International Development (#AID-OAA-A-11-00051)
  • National Institutes of Health (1 R56 AI108368-01)

This publication has 16 references indexed in Scilit: